News & Resources

The Value of KOLs in Oncology and Hematology

Pharma and biotech companies thrive on communication with key opinion leaders (KOLs). However, connecting with these individuals can be a challenge. Identifying your outreach goals helps eliminate logistic roadblocks. Once you have your organization’s goals in mind, you can seek out individuals who can help you on the path to success. Read on to learn more about what KOLs can do for your organization and how to make the most of these valuable relationships.

Identifying KOLs
When planning their outreach efforts, most companies scramble to connect with world-famous oncologists. Internationally recognized experts are alluring, and your company may be eager to speak to one of these “big names,” but these KOLs have many demands on their time, and they’re often difficult to reach.

Fortunately, practicing physicians aren’t the only thought leaders around. Anyone with profound experience and influence in the medical community may be a useful point of contact. Members of the cancer care team can be KOLs, and medical directors and clinical pharmacists also have significant influence.

As medical costs continue to rise, consider reaching out to KOLs who make decisions for large health plans. Managed-care leaders and pharmacy benefit managers are influential and drive formulary decision-making. Connecting with these individuals can help your organization overcome barriers that prevent your drug or medical device from reaching the market.

The Role of KOLs
The field of hematology/oncology has only grown more specialized in recent years. A wealth of information is available to clinicians, but there isn’t enough time to develop expertise in every subspecialty. As a result, community oncologists turn to experts for guidance and resources.

There’s no doubt that KOLs guide decision-making within the hematology/oncology community. Clinicians, patients, and caregivers rely on these experts to guide their treatment decisions. KOLs can also boost participation in clinical trials and ensure their success, but not all of these thought leaders offer your organization equal expertise.

When planning your outreach, consider who has the highest level of expertise within your subspecialty. Practicing physicians usually play a critical role, but other individuals may also hold some sway. In recent years, journalists, academics, health authority reps, and members of patient advocacy groups have gained a powerful voice. Practicing physicians often listen carefully to their opinions, and these KOLs can give your organization a fresh perspective.

Engaging With KOLs
Once your organization has identified the most valuable KOLs, you need an outreach strategy. Many companies rely on marketing software to help with these tasks, but not all software systems allow for targeted outreach. Some KOLs may also be reluctant to connect with marketing experts. So what’s the best way to connect with KOLs? Consider the following strategies:

  • Use Medical Liaisons
    KOLs are often skeptical of anything that sounds like a sales pitch, but medical liaisons can connect with physicians on a peer-to-peer level. Liaisons offer a unique combination of medical and business skills. Experienced medical liaisons build partnerships with KOLs, sharing medical knowledge and expertise. During this partnership, they can trade resources and data. This relationship can last for years, providing your company with ongoing insight.
  • Get Creative About Communication
    Face-to-face meetings are still ideal for connecting with clinicians. However, busy oncologists seldom have time for in-person meetings. Geographic distance can also be a barrier. Digital channels help to bridge the gap. Your blog and social media accounts can provide valuable information to KOLs. Online meeting tools and digital communication platforms also allow virtual access to KOLs across the globe.
  • Do Your Homework
    Today, most KOLs focus on one subspecialty. Their in-depth expertise in their chosen field can be an invaluable resource. During your outreach efforts, familiarize yourself with each KOL’s interests and activities. Too often, KOLs receive formulaic requests or copy-and-pasted communications. These outreach efforts are not likely to spark a response.
    Your medical directors and medical liaisons are invaluable when it comes to personalized outreach. A medical liaison can initiate peer-to-peer discussions about a KOL’s area of expertise. Their in-depth scientific knowledge makes the most of an expert’s limited time.
  • Leverage Connections Between KOLs
    KOLs boast a vast network of colleagues and patients. If you build relationships with the right KOLs, your organization can make dozens of useful contacts. Your chosen KOL may help you spark interest in new drugs or encourage participation in your trial. This tightly knit network can be a double-edged sword, however. Because the top KOLs are so well-connected, one misstep can destroy countless relationships. Professional, circumspect communication is essential. Medical liaisons may be useful in this area, too.
  • Incorporate KOL Feedback Early On
    Pharma and biotech companies often seek out KOLs toward the later stages of clinical trials, when their drug or product is almost ready to hit the market. Although KOLs can still offer valuable feedback at this point, delayed outreach can waste time and money. By the time you receive expert feedback, it may be too late to correct mistakes or limit costs. Engaging with KOLs throughout the development cycle helps streamline this process. Successful organizations establish scientific collaboration and build interest before the development process even begins. KOLs have the expertise needed to structure clinical trials and avoid costly mistakes. Some may also be willing to assume the role of principal investigator. Initiating outreach early on protects your organization’s valuable resources. By incorporating feedback from KOLs into early initiatives, you can profit from their expertise.

Dig Deep Into Advisory Boards
Advisory boards and committees provide feedback on a wide range of topics. They usually include practicing physicians who can offer real-world data and discuss factors that affect a clinician’s willingness to prescribe new treatments. Including KOLs in these groups ensures that you receive on-the-ground feedback.

The Axess Network: Streamline Your Outreach
Live meetings offer unparalleled opportunities for connection, but they aren’t always feasible. Social networking and tech-enabled solutions are excellent alternatives. Your organization needs a time-sensitive, cost-effective method for connecting with experts.

Aptitude Health’s Axess Network provides access to over 600 global scientific and clinical thought leaders, and 1,500+ practicing physicians, covering all major tumor types and hematologic malignancies.

Using the Axess Network, Aptitude Health’s OncoBoard online collaboration platform provides life science companies a closed online platform for rapid answers to immediate questions from industry-recognized KOLs and community physicians. It allows for customizable content, including multiple question types, digital stimuli, and discussion tools to bring thoughts and opinions to the forefront. Life science partners receive comprehensive insights within a week of project completion.

Therapeutic Area

Archives

Matthew Gordon

VP, Real-World Evidence
Matthew has more than 25 years of experience in real-world evidence and observational, non-interventional research. He has led studies across the full life cycle—from startup through publication—supporting objectives that range from understanding a disease’s natural history to fulfilling global safety surveillance requirements. Matthew brings deep expertise in orphan disease programs, having overseen more than 25 long-term, global initiatives, as well as in disease and product registries, prospective pharmacoeconomic studies, and systematic literature reviews. Matthew leads the RWE Registries team, responsible for building the business and team. Prior to joining Aptitude Health, he held senior leadership roles at Parexel, Worldwide Clinical Trials, inVentiv Health Clinical, Quintiles Outcome, and ICON Clinical Research. Matthew holds a BA in sociology from Boston University, is a long-standing member of the International Society for Pharmacoeconomics and Outcomes Research (ISPOR), and is a frequent speaker at ISPOR, the Center for Business Intelligence, and related industry conferences.

Gerald Stanvitch, PhD

VP, Scientific Content

Cate Browning, PhD

VP, Global Medical Affairs

Erin Zingales Rau

VP, Account Services

Kelly Kocor

VP, People & Culture
Kelly leads both the human resources and talent acquisition teams, ensuring that Aptitude Health attracts, retains, and develops top personnel to drive our continued success. With over 17 years of experience transforming global HR initiatives, Kelly is an expert in harmonizing HR policies and fostering a culture of engagement and partnership. She is committed to partnering with all areas of the business to ensure full regulatory compliance and delivering value-added services to our organization and its people. Kelly is passionate about developing and implementing HR strategies that help support our employees’ professional and personal growth. She is dedicated to fostering a culture that encourages innovation, collaboration, and inclusivity, helping Aptitude Health continue to be a great place to work.

Bart Zygmond

VP, Finance
Bart brings a wealth of experience to the organization, having worked in the life sciences, pharmaceuticals, manufacturing, and service industries. With his expertise in financial reporting, US GAAP, SOX, cash flow modeling, and financial analysis, he plays a crucial role in the company’s financial management and strategy. Prior to joining Aptitude Health as VP, Finance, Bart held several controller positions: at Q2 Solutions, he oversaw the global finance team and financial operations, ensuring the accurate and timely financial reporting of the company. He also held controller positions at Domtar Inc and Veristat.

Eugene Vissers, MD

Senior VP, Global Scientific Content
Eugene is a seasoned medical doctor with over 20 years of international experience in pharma, consultancy, and agency environments. Eugene leads the US team of dedicated experts responsible for developing high-quality medical content. Prior to joining Aptitude Health, Eugene served as medical director at Ipsen and AstraZeneca. With both his medical degree and an MBA, Eugene brings a unique perspective to his role. His clinical background, combined with his business acumen, allows him to develop innovative strategies that drive results. Under Eugene’s leadership, the medical content team delivers scientific information of the highest quality, providing valuable insights to our clients around the world.

Adrian Barfield

VP, US Business Development

Kelley Hernandez

Executive VP, US Business Development
Kelley has over 18 years of experience in the oncology space. Kelley joined Aptitude Health after working with Cardinal Health, where she was part of the Healthcare and Analytics Division, and finished her tenure there with VitalSource™ (GPO division). As the leader of the strategic business development team for the US, Kelley brings a wealth of expertise to the organization. Her experience in the healthcare industry, combined with her ability to identify and capitalize on new business opportunities, is invaluable in driving the company’s growth and success. Kelley’s dedication to building strong relationships with life science partners is a testament to her commitment to delivering exceptional value to the healthcare industry.

Adam Sinensky, MBA

Chief Technology Officer

Adam has over 20 years of experience in the healthcare industry and an MBA in healthcare management. After 10 years as a strategy consultant to life science companies, Adam has spent the last decade as a product and strategy leader focused on bringing technology products to market across the payor, provider, and life sciences segments. By combining his business acumen and experience working directly with software developers, engineers, and data scientists, Adam has successfully led numerous product launches and enhancements from ideation to development and go-to-market initiatives. His product and change management expertise has led organizational shifts from services to technology at companies such as Change Healthcare and Datavant/Ciox. At Aptitude Health, Adam is responsible for growing our portfolio of product offerings by leveraging real-world data and artificial intelligence with our existing solutions and industry-leading Axess Network of healthcare providers. He also oversees our IT and cybersecurity teams.

Stefanie Daniels

Chief Commercial Officer

Stefanie is a seasoned healthcare executive with over 20 years of experience in oncology. She brings a wealth of knowledge and expertise to the organization. Stefanie joined Aptitude Health after spending over a decade as a senior director at Physicians’ Education Resource, an oncology CME vendor. During her tenure, she led and managed teams responsible for grant development/acquisition, program creation/execution, and faculty management. Stefanie’s deep understanding of the oncology industry and her ability to lead teams through complex projects make her a vital part of the organization’s success. Her dedication to providing high-quality solutions to our life science partners is a testament to her commitment to improving cancer patient care.

Jason Cash

Chief Financial Officer

Jason is an accomplished finance professional with over 20 years of experience in the pharmaceutical services industry. Throughout his career, he has demonstrated a keen ability to navigate high-growth organizations, delivering exceptional results. Before joining Aptitude Health, Jason served as the CFO of Veristat International, a global contract research organization. In this role, he led the financial strategy and played a pivotal role in driving the company’s growth and success. Jason’s wealth of experience and expertise in financial management make him an essential member of the leadership team. His strategic thinking and ability to drive results are highly respected within the industry.

Jez Moulding

Chief Executive Officer
Jez is a seasoned leader with over 20 years of experience in general management and regional president roles. He has a proven track record of success in the healthcare industry, having worked in the US, Japan, Australia, Korea, South Africa, France, and the UK for Sanofi, where he supported the launch of 10 new drugs across various therapeutic areas. As chief commercial officer at UDG Healthcare and EVP at Ashfield, Jez demonstrated his expertise in developing and implementing successful business strategies. He joined Aptitude Health from Pharmaspectra, an IQVIA business, where he served as CEO since 2018. Jez’s extensive experience in the pharmaceutical industry and his leadership skills make him an invaluable asset to the organization.